Market research
CRL Charles River Laboratories
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 281
- Dividend yield
- Not available
- Beta
- 1.38
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US1598641074
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 281
- Dividend yield
- Not available
- Beta
- 1.38
About
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and de
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CRL discussion.
5 years, 4 months ago
Charles River Laboratories International, Inc is currently in a long term uptrend where the price is trading 32.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.2.
Charles River Laboratories International, Inc's total revenue rose by 14.4% to $791M since the same quarter in the previous year.
Its net income has increased by 79.8% to $144M since the same quarter in the previous year.
Finally, its free cash flow fell by 4.5% to $112M since the same quarter in the previous year.
Based on the above factors, Charles River Laboratories International, Inc gets an overall score of 4/5.